Toxicities, Body Composition, and hrQoL Among Long-Term Survivors Treated With Antibodies to PD-1 and PD-L1
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Survivorship in Immune Therapy: Assessing Toxicities, Body Composition and Health-Related Quality of Life Among Long-Term Survivors Treated With Antibodies to Programmed Death-1 Receptor and Its Ligand
Eur. J. Cancer 2020 Jun 26;135(xx)211-220, JR Patrinely, AC Young, H Quach, GR Williams, F Ye, R Fan, L Horn, KE Beckermann, EA Gillaspie, JA Sosman, DL Friedman, JJ Moslehi, DB JohnsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.